Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo.

@article{Patel2004PretreatmentWE,
  title={Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo.},
  author={Nimesh S. A. Patel and Edward J. Sharples and Salvatore Cuzzocrea and Prabal Kumar Chatterjee and Domenico Britti and Muhammad Magdi Yaqoob and Christoph Thiemermann},
  journal={Kidney international},
  year={2004},
  volume={66 3},
  pages={983-9}
}
BACKGROUND Erythropoietin (EPO) is a potent stimulator of erythroid progenitor cells and is known to be up-regulated during states of hypoxia. Here we investigate the effects of renal ischemia/reperfusion (I/R) on the degree of renal dysfunction and injury with recombinant human EPO in mice when given as either a 3-day pretreatment, or upon reperfusion of the kidney. METHODS Mice were treated with EPO (1000 IU/kg/day subcutaneously) for 3 days, or treated with EPO (1000 IU/kg subcutaneously… CONTINUE READING